Clinical Trials - Latest News and Updates on Clinical Trials

Insilico Medicine Advances ISM8969 Into Phase 1 Trial as Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation

Yuvraj — Fri, 19 Jun 2026 07:39:02 +0000

Insilico Medicine has reached a significant clinical milestone with the completion of first-in-human dosing of ISM8969 in a Phase 1 study. Conducted in collaboration with Hygtia Therapeutics, the ISM8969 Phase 1 trial marks the transition of this oral, brain-penetrant NLRP3 inflammasome inhibitor from preclinical development into human evaluation. The compound is designed to address chronic […]

The post Insilico Medicine Advances ISM8969 Into Phase 1 Trial as Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation first appeared on World Pharma Today.

Boehringer’s Survodutide Cuts Visceral and Liver Fat While Preserving Lean Mass in Late-Stage Trial

Yuvraj — Tue, 09 Jun 2026 07:45:56 +0000

German pharmaceutical company Boehringer Ingelheim has reported that its experimental obesity drug, survodutide, significantly reduced visceral abdominal fat and liver fat while largely preserving lean body mass in a late-stage clinical study. The data strengthens the company’s argument that the drug offers meaningful health benefits beyond overall weight loss percentage a distinction that analysts have […]

The post Boehringer’s Survodutide Cuts Visceral and Liver Fat While Preserving Lean Mass in Late-Stage Trial first appeared on World Pharma Today.

MSD and Adcendo Initiate Phase Ib Collaboration for Solid Tumours

Yuvraj — Fri, 29 May 2026 13:23:20 +0000

MSD and Adcendo have established a collaboration and supply agreement to evaluate the combination of ADCE-T02 and pembrolizumab. The companies are preparing for a Phase Ib solid tumour clinical trial targeting patients with advanced solid tumours. Adcendo will act as the sponsor for the solid tumour clinical trial, with MSD providing pembrolizumab. ADCE-T02 is an […]

The post MSD and Adcendo Initiate Phase Ib Collaboration for Solid Tumours first appeared on World Pharma Today.

Decentralized Clinical Trials Market Advances Worldwide

Yuvraj — Wed, 20 May 2026 10:35:31 +0000

The global Decentralized Clinical Trials Market is expected to grow from USD 9.74 billion in 2025 to USD 34.13 billion by 2035, registering a compound annual growth rate (CAGR) of 13.36% during the forecast period from 2026 to 2035. The market is expanding as pharmaceutical companies, biotechnology firms, contract research organizations, and healthcare technology providers […]

The post Decentralized Clinical Trials Market Advances Worldwide first appeared on World Pharma Today.

Algeria and Hungary Enhance Pharmaceutical Industry Collaboration via R&D and Clinical Trials

Yuvraj — Tue, 19 May 2026 13:26:27 +0000

In a strategic move to bolster the national pharmaceutical industry, the Algerian Minister of Pharmaceutical Industry, Mr. Wassim Kouidri, convened with the Ambassador of the Republic of Hungary, Mr. Gábor Levente Szarka, this Sunday in Algiers. The high-level discussions centered on intensifying bilateral cooperation between the two nations, with a specific focus on research and […]

The post Algeria and Hungary Enhance Pharmaceutical Industry Collaboration via R&D and Clinical Trials first appeared on World Pharma Today.

Quantum Computing Enhancing Clinical Trial Design

Yuvraj — Sat, 02 May 2026 06:20:31 +0000

The modernization of clinical development is undergoing a massive shift as quantum-based optimization tools are integrated into trial architectures. By improving patient selection and simulating physiological responses at a molecular level, these technologies are reducing the high failure rates associated with traditional research phases. This evolution toward digital and adaptive trials ensures that therapeutic candidates are tested more efficiently, leading to faster regulatory approvals and a more streamlined path for delivering life-saving treatments to the public.

The post Quantum Computing Enhancing Clinical Trial Design first appeared on World Pharma Today.

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

Yuvraj — Fri, 01 May 2026 10:18:20 +0000

The U.S. Food and Drug Administration has unveiled a new regulatory initiative to enable real-time clinical trials, marking a structural shift in how drug development data is reviewed. The program, already supported by AstraZeneca and Amgen, introduces a model where safety and efficacy data are transmitted continuously to regulators rather than submitted after trial completion. […]

The post FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen first appeared on World Pharma Today.

Early Phase Decisions Drive Faster Drug Development

Yuvraj — Thu, 23 Apr 2026 06:13:33 +0000

Strategic early-stage planning and rigorous regulatory readiness serve as the foundation for accelerating pharmaceutical timelines and optimizing long-term R&D efficiency.

The post Early Phase Decisions Drive Faster Drug Development first appeared on World Pharma Today.

Smarter Trial Design Improves Drug Development Speed

Yuvraj — Wed, 22 Apr 2026 11:46:47 +0000

Optimization of clinical trial protocols through innovative designs and strategic endpoint selection directly accelerates drug development speed and improves operational reliability.

The post Smarter Trial Design Improves Drug Development Speed first appeared on World Pharma Today.

Data Driven Decisions Improve Drug Development Outcomes

Yuvraj — Wed, 22 Apr 2026 11:43:21 +0000

Integrating comprehensive analytics and real-world data into clinical planning allows pharmaceutical companies to optimize trial design and significantly improve patient outcomes.

The post Data Driven Decisions Improve Drug Development Outcomes first appeared on World Pharma Today.